地塞米松植入剂玻璃体腔注射后眼压升高的长期发生率与危险因素:SAFODEX-2研究
平均随访30个月,OHT发生率为32.6%,36.9%的眼需降眼压治疗,其中97%仅局部用药即可控制。年轻、男性、葡萄膜炎、视网膜静脉阻塞及需双联或三联局部降眼压药治疗的眼压升高为危险因素,重复注射不增加OHT风险(P=0.248)。
要点
- 地塞米松植入剂注射后OHT发生率为32.6%,平均随访30个月。
- 97%的OHT仅需局部降眼压药物即可控制。
- 重复注射不增加OHT风险(P=0.248)。
核心结论
- 地塞米松植入剂玻璃体腔注射后OHT发生率为中等水平,呈一过性,局部治疗可控制。
- 重复注射地塞米松植入剂既不增加也不降低OHT风险(P=0.248)。
研究设计与样本
- 回顾性分析2010年10月至2015年2月期间至少接受一次地塞米松植入剂玻璃体腔注射的患眼。
主要发现
- OHT发生率为32.6%,定义为眼压>25 mmHg和/或较基线升高10 mmHg。
- 36.9%的患眼需降眼压治疗,其中97%仅局部用药即可控制。
- OHT发生率不随注射次数增加而改变,无累积效应(P=0.248)。
关键数值与推荐
- OHT定义:眼压>25 mmHg和/或随访期间较基线眼压升高10 mmHg。
- OHT危险因素:年轻、男性、葡萄膜炎、视网膜静脉阻塞、需双联或三联局部降眼压药治疗的眼压升高。
临床怎么用
- 地塞米松植入剂注射后应监测眼压,尤其对年轻、男性、葡萄膜炎、视网膜静脉阻塞及需联合降眼压治疗的患者。
- 多数OHT可通过局部降眼压药物控制,重复注射不因累积效应而增加OHT风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the incidence, risk factors, and time to onset of ocular hypertension (OHT) after intravitreal injections (IVI) of dexamethasone implant and to evaluate the long-term cumulative probability of intraocular pressure elevation. METHODS: Eyes of patients having received at least one dexamethasone implant IVI between October 2010 and February 2015 were included in the present study. Ocular hypertension was defined as intraocular pressure > 25 mmHg and/or an increase of 10 mmHg over the follow-up period compared with baseline intraocular pressure. RESULTS: Four hundred ninety-four eyes were studied in 410 patients. For a total of 1,371 IVI, the incidence of OHT was 32.6% in the study eyes with a mean follow-up period of 30 months (3-62.5) and a median follow-up of 29 months. Pressure-lowering treatment was introduced for 36.9% of eyes. Topical treatment alone was sufficient to manage OHT in 97%. Young age, male sex, uveitis and retinal vein occlusion, and glaucoma treated with a double- or triple-combination topical pressure-lowering medication were found to be risk factors for OHT. The incidence of OHT did not change with an increase in the number of IVI, and there was no cumulative effect, defining by an increase of the incidence of OHT in patients after repeated IVI (P = 0.248). CONCLUSION: This study confirmed that OHT is of moderate incidence, transient, controlled by topical treatment and provides data on the long-term cumulative probability of intraocular pressure elevation in a large cohort of eyes treated with dexamethasone implant IVI. Repeat injections of dexamethasone implant neither increase nor decrease the risk of OHT.
引用
- Rezkallah A, Mathis T, Abukhashabah A, et al. LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY. Retina. 2021. PMID: 33315814. doi:10.1097/IAE.0000000000003080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。